Outlook TherapeuticsOTLK
About: Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Employees: 23
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
90,150% more call options, than puts
Call options by funds: $3.61M | Put options by funds: $4K
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
8% less funds holding
Funds holding: 66 [Q3] → 61 (-5) [Q4]
17.16% less ownership
Funds ownership: 35.41% [Q3] → 18.25% (-17.16%) [Q4]
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
81% less capital invested
Capital invested by funds: $44.7M [Q3] → $8.59M (-$36.2M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Ascendiant Capital Edward Woo 28% 1-year accuracy 23 / 81 met price target | 1,500%upside $24 | Buy Maintained | 24 Feb 2025 |
HC Wainwright & Co. Douglas Tsao 18% 1-year accuracy 31 / 171 met price target | 100%upside $3 | Buy Maintained | 18 Feb 2025 |
Chardan Capital Daniil Gataulin 21% 1-year accuracy 10 / 48 met price target | 100%upside $3 | Neutral Maintained | 18 Feb 2025 |
Financial journalist opinion









